For example, pro-oxidant drugs can treat pancreatic cancer with p53 mutation [3], and troglitazone can enhance the anticancer effect of IFN-β through the interaction of STAT-3 dependent survival pathway and directly induce the increase of p21 and p27 expression [4]. The gene discussed is CDKN1B; the disease is familial pancreatic carcinoma.